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Abstract 
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated cell lysis 
due to deficiency of GPI-anchored complement regulators. Blockage of the lytic pathway by 
eculizumab is the only available therapy for PNH patients and shows remarkable benefits, but 
regularly yields PNH erythrocytes opsonized with fragments of complement protein C3, 
rendering such erythrocytes prone to extravascular hemolysis. This effect is associated with 
insufficient responsiveness seen in a subgroup of PNH patients. Novel C3-opsonin targeted 
complement inhibitors act earlier in the cascade, at the level of activated C3 and are engineered 
from parts of the natural complement regulator Factor H (FH) or complement receptor 2 (CR2). 
This inhibitor class comprises three variants of “miniFH” and the clinically developed “FH-CR2” 
fusion-protein (TT30). We show that the approach of FH-CR2 to target C3-opsonins was more 
efficient in preventing complement activation induced by foreign surfaces, whereas the miniFH 
variants were substantially more active in controlling complement on PNH erythrocytes. Subtle 
differences were noted in the ability of each version of miniFH to protect human PNH cells. 
Importantly, miniFH and FH-CR2 interfered only minimally with complement-mediated serum 
killing of bacteria when compared to untargeted inhibition of all complement pathways by 
eculizumab. Thus, the molecular design of each C3-opsonin targeted complement inhibitor 
determines its potency in respect to the nature of the activator/surface providing potential 
functionality in PNH. 
 
Introduction 
In absence of strict regulation the triggering of any of the three complement activation pathways, 
the lectin (LP), the classical (CP) or the alternative pathway (AP) can lead to the initiation of the 
lytic, terminal pathway (TP) (Supplemental Figure 1A). Due to the deficiency in producing 
glycosylphosphatidylinositol (GPI) anchors, PNH cells lack the two important membrane-based 
complement regulators CD55 (Davitz et al., 1986; Nicholson-Weller et al., 1983; Pangburn et al., 
1983) and CD59 (Holguin et al., 1990, 1989) leaving PNH erythrocytes susceptible to 
complement-mediated lysis (reviewed in (Parker, 2007)). CD55 is a potent regulator of all 
convertases throughout the proximal complement cascade (Sun et al., 1999; Telen and Green, 
1989), while CD59 specifically inhibits the formation of the membrane attack complex (MAC) 
(Davies et al., 1989), which introduces lytic pores into cell membranes. The CP is typically 
initiated by the sensing of immune complexes, but can, similarly to the LP, also be launched by 
recognition of pathogen or danger patterns. In contrast the AP is continuously and 
indiscriminately activated at low level (which is also called “tick-over” activation) posing a 
constant threat to vulnerable cells (reviewed in (Ricklin et al., 2010)). Yet the AP is not merely 
one of the three complement activation pathways, but functions as a positive feedback loop to all 
initiation pathways and amplifies the C3 activation product C3b regardless of the underlying 
activation pathway that produced the initial C3b molecules (reviewed in (Lachmann, 2009)). 
 
Selectivity within the AP is achieved by providing healthy host cells with a set of 
regulators that tightly control AP amplification on such surfaces. On PNH cells, complement 
receptor 1 (CR1) is the only remaining membrane anchored AP regulator on the cell surface. The 
number of CR1 molecules on erythrocytes differs considerably and in Caucasians correlate with a 
restriction fragment length polymorphism (Xiang et al., 1999). Low numbers of CR1 molecules 
on PNH erythrocytes correlate with reduced complement control and higher numbers of C3- 
opsonins being fixed to PNH erythrocytes, which predisposes those erythrocytes for clearance by 
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the reticuloendothelial system, a phenomenon termed “extravascular hemolysis” (Rondelli et al., 
2014). The reduced set of surface-bound regulators puts more emphasis for protecting PNH 
erythrocytes from complement on the soluble AP regulator Factor H (FH). Owing to its ability to 
recognize sialic acid moieties located on erythrocytes, FH was shown to be a crucial contributor 
to the protection of PNH erythrocytes (Ferreira and Pangburn, 2007). While FH and CR1 appear 
to provide sufficient protection of PNH erythrocytes from AP tick-over activation under steady 
state conditions, after initiation of the complement cascade by a stimulus (e.g. infection or 
surgery) (Peffault de Latour et al., 2015) the two remaining complement regulators are 
overwhelmed and fail to sufficiently control bystander AP activation on the PNH surface (Ezzell 
et al., 1991; Ferreira and Pangburn, 2007; Rondelli et al., 2014). This situation of relative underregulation 
of complement renders PNH cells, but not healthy host tissue, susceptible to lysis by 
the AP. 
 
Therapy with eculizumab (Soliris, Alexion Pharmaceuticals), a humanized monoclonal 
antibody directed against terminal complement component C5, inhibits MAC formation and thus 
intravascular lysis (Rother et al., 2007) (Supplemental Figure 1B). Despite the clear benefits of 
complete blockage of complement TP for PNH patients (Brodsky et al., 2008; Hillmen et al., 2006; Kelly et 
al., 2011), the high treatment cost, insufficient response in some patients and 
increased risk for meningococcal infections need to be considered. Whereas the infection risk 
may be reduced through use of a vaccination panel (Verhave et al., 2014), residual anemia 
remains an issue for a substantial fraction of patients. Under eculizumab treatment, C5 inhibition 
prevents MAC formation and intravascular lysis, but due to an under-controlled proximal AP 
(absence of CD55), AP-triggered C3-opsonization (covalent attachment of C3 activation 
fragments) of PNH erythrocytes has been observed (Höchsmann et al., 2012; Risitano et al., 
2009). C3 opsonization of PNH erythrocytes is a finding seen only in eculizumab treated patients 
(it is assumed that, prior to therapeutic C5-inhibition, PNH erythrocytes fixing C3-opsonins 
would lyse immediately - being unavailable for detection). C3-opsonised PNH erythrocytes 
suffer from reduced circulation half-life due to clearance via extravascular hemolysis through 
phagocytosis by tissue macrophages in spleen and liver (Risitano et al., 2009). Whereas C3b and 
its degradation product iC3b are the primary phagocytic opsonins, the accumulation of the endstage 
opsonin C3dg on circulating PNH erythrocytes in patients receiving anti-C5 therapy may 
further facilitate clearance via interaction with complement receptor 3 on phagocytes, as a recent 
in vitro study shows (Lin et al., 2015). Importantly, the level of “extravascular hemolysis” 
correlates negatively with the hematologic response to eculizumab in a substantial fraction of 
patients (Hill et al., 2010; Risitano et al., 2011, 2009). 
 
To prevent opsonization and extravascular hemolysis of PNH cells, novel complement 
inhibitors were developed that block at the point of C3 activation; some of these inhibitors were 
shown to efficiently inhibit both intravascular hemolysis and opsonization in preclinical PNH 
models (Risitano et al., 2014, 2012; Schmidt et al., 2013). With the potential safety profile in 
mind a new class of bioengineered inhibitors was constructed to specifically block only the PNH implicated 
AP of complement activation keeping the CP and LP intact for immunological 
surveillance (Supplemental Fig. 1C). Apart from regulating complement at the level of C3b (i.e. 
activated C3) by utilizing N-terminal domains of the natural regulator FH (Schmidt et al., 2007) 
these inhibitors possess various strategies to also bind efficiently to C3b’s degradation products 
iC3b and C3dg, which occur frequently on sites of ongoing complement turnover on vulnerable 
host tissue (e.g. PNH cells that have at least a residual set of complement regulators) (Risitano et 
al., 2012; Schmidt et al., 2013). By targeting AP-specific inhibitors directly to vulnerable cells, 
4 
 
local AP-inhibitory capacity is markedly increased while systemic AP activity is less affected, 
thus apparently preventing increased susceptibility to infection (Atkinson et al., 2005). 
The in vitro and ex vivo studies presented here simultaneously compare the ability of four 
different AP-specific complement inhibitors to selectively target to C3-opsonized (C3b, iC3b, 
C3dg) surfaces and protect PNH erythrocytes. The regulators under investigation are: FH-CR2, 
an analog of the inhibitor TT30 (Fridkis-Hareli et al., 2011) and three inhibitors that underwent 
different levels of engineering and are denominated miniFH versions 1, 2 and 3 (Fig. 1A). In 
terms of regulating the AP (via C3b) FH-CR2 and miniFH proteins all utilize N-terminal portions 
of the natural regulator FH (Schmidt et al., 2007). In regards to targeting to C3-inactivation 
products, FH-CR2 relies on an N-terminal portion of the complement receptor 2 (CR2), while the 
miniFH approach utilizes C-terminal portions of FH. The simultaneous evaluation of all four C3-opsonin 
targeted inhibitors on various non-native and native surfaces and the comparison to 
eculizumab in a bactericidal serum killing assay identifies the targeting mechanisms with highest 
selectivity and efficiency for human erythrocytes in vitro, revealing important considerations for 
the engineering of complement targeted inhibitors. 
 
 
Material and Methods 
Human erythrocytes 
PNH erythrocytes were collected by venipuncture from a PNH patient and used immediately in the AP 
lysis assay. This project was conducted under the ethic approval 279/09 granted from the ethics 
commission of Ulm University. 
 
Proteins 
FH was purchased from CompTech (Tyler, USA). MiniFH-1 (Schmidt et al., 2013), miniFH-2 (Hebecker 
et al., 2013) and miniFH-3 (Nichols et al., 2015) were obtained as published. FH-CR2 was generated by 
PCR amplification of CCP1-4 of CR2 from plasmid BillNeo-hCR2-E-E (gift from Prof Mike Holers, 
Denver, USA) and CCPs1-5 from an in-house vector containing the complete FH cDNA (NP_000177.2); 
the PCR products were cloned into pDR2EF1α-nMCS vector (Charreau et al., 1994; Yanagawa et al., 
2003). The construct was sequence verified and transfected into Chinese Hamster Ovary (CHO) 
cells using jetPEI (Polyplus, VWR, Leicestershire, UK) following standard protocols. FH-CR2 
was purified from transfected CHO cell culture supernatants using nickel-affinity chromatography (GE 
Healthcare) followed by an OX-24 affinity-column and size exclusion chromatography. Eculizumab was 
obtained from remnants left in the infusion pipe. The concentration of eculizumab was determined by 
measuring the OD280nm employing a standard extinction coefficient for IgG antibodies of 210,000 M-1 
cm-1. 
 
ELISA 
ELISAs measuring the complement inhibition activities of the various inhibitors were based on standard 
methods and performed as described (Schmidt et al., 2013). In brief, 50 μl of a LPS solution (50 μg/ml) 
from Salmonella typhimurium (Sigma-Aldrich) were coated on 96-well plates in PBS (pH 7.4) for 2 h at 
RT or overnight at 4°C followed by washing (PBST: PBS containing 0.05% Tween 20) and blocking (1% 
BSA in PBS). In a 96-well plate analytes in PBS (30 μl) were mixed with 30 μl of 50% serum containing 
10 mM MgEGTA to block CP/LP activation. The final serum content was 25%. The mix was incubated 
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for 1.5 h at 37 °C prior to washing (2xPBST) and detection with exposure to goat anti-human C3 (HRP 
conjugate from MP Biomedicals) at a 1:1000 dilution in 1% BSA/PBS. Further washing (3xPBST) was 
followed by detection with a solution of ABTS (0.5 mg/ml; Roche) and 0.03% H2O2 in 0.1 M sodium 
citrate buffer at pH 4.3. Absorbance was read at 405 nm. EDTA at a final concentration of 5 mM and PBS 
were used as negative and positive controls, respectively. 
 
PNH hemolysis assay 
Patient blood was collected in EDTA. Erythrocytes were washed with PBS. ABO-matched serum was 
obtained from healthy volunteers (ethic approval 155/12, Ulm University) or German Red Cross 
BloodTransfusion Service Baden-Württemberg-Hessen and shock-frozen and stored at -80 ºC prior to 
use. 
For each assay, 2 μl of washed and packed PNH erythrocytes were incubated with a mix of 8 μl of 
inhibitors or controls in PBS and 30 μl of HCl-acidified serum (pH 6.6–6.9) with addition of MgCl2 to 1.5 
mM. The hematocrit approximated 8%, the final serum content was 75%. Lowering the pH triggers brisk 
activation of the AP (Ezzell et al., 1991). Samples were incubated for 24 h at 37°C. Hemolysis of PNH II 
and III erythrocytes was measured by flow cytometry with an phycoerythrin-coupled anti-CD59 antibody 
(Clone OV9A2; e-Bioscience) similarly as described before (Höchsmann et al., 2011; Schmidt et al., 
2013). The level of hemolysis of PNH II and III erythrocytes at the different inhibitor concentration points 
was normalized to the lysis of PNH II and III erythrocytes observed in acidified serum alone (i.e. in 
absence of any spiked inhibitors or controls). 
 
Rabbit erythrocyte hemolysis assay 
30 μl of a serum/MgEGTA mix (with serum being derived from three healthy donors) were mixed with 4 
μl of inhibitors or controls in PBS and 6 μl of a rabbit erythrocyte (CompTech or TCS) suspension in 
PBS/Mg-EGTA. The final serum content was 75%. This mixture was incubated for 30 min at 37 °C. 
Reactions were stopped with 120 μl ice-cold PBS/EDTA (5 mM). Hemolysis was determined by reading 
the OD405 of 100μl supernatant. 
 
Bacterial killing assays 
XL1-Blue (Stratagene) E. coli containing the pPICZαB plasmid, which confers resistance to Zeocin, were 
grown in LB-medium until an OD600 of 0.6 was reached, were washed in PBS and then incubated for 1 h 
in NHS spiked with PBS (as control) or complement inhibitors dissolved in PBS at the indicated final 
concentration. Colony forming units were evaluated by colony counting after plating 10 to 10000-fold 
serial dilutions on selective LB (low salt) medium containing Zeocin at a final concentration of 25 μg/ml. 
 
Blood polymorphism genotyping and erythroid CR1 levels 
CR1 levels on erythrocytes vary between individuals. In Caucasians a restriction fragment length 
polymorphism in an intron of the CR1 gene has been identified to correlates with the number of CR1 
molecules on erythrocytes (Wilson et al., 1986). Subsequently, a single nucleotide polymorphism (SNP) 
within exon 22 (A3650G) in the CR1 gene was linked to high CR1 expression (H, high allele) or low CR1 
expression (L, low allele) (Xiang et al., 1999). Homozygous HH individuals have higher erythrocyte 
surface levels of CR1 (>1000), homozygous LL individuals have <200 molecules per erythrocyte, and HL 
individuals having intermediate CR1 surface levels (a comprehensive table that lists CR1 SNPs is found in 
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(Schmidt et al., 2015)). To test the CR1 phenotype of the PNH erythrocytes 200 μl of whole blood from 
the PNH patient or a healthy control were used to extract DNA using the QIAamp DNA Blood Mini Kit 
(Qiagen). Samples were genotyped for the SNP (A/G) in the CR1 gene at nucleotide 3650 in exon 22, 
which was analysed by restriction enzyme digest by RsaI, as described in (Tham et al., 2010; Xiang et al., 
1999). In brief, a 682 base pair spanning sequence within exon 22 was amplified via PCR using the cloned 
Pfu® DNA Polymerase (Agilent Technologies) according to the suppliers protocol and the forward primer 
5’-ttcacattggatagccagagc-3’ and the reverse primer 5’-ccagaggttaatctccctgga-3’. The restriction digest 
with 
RsaI (NewEnglandBiolabs) was performed according to the supplier’s specifications and analysed by 
agarose gel electrophoresis using SYBR® safe DNA stain (Thermo fisher scientific) for visualisation of the 
DNA bands. The A3650 SNP corresponds to the HH phenotype and yields restriction fragments of 520 
and 162 base pair length while the G3650 SNP produces 458, 162, 62 base pair fragments. Erythrocytes 
from both donors were also submitted to analysis by flow cytometry to analyse the surface expression of 
CR1. Cells were stained with a mouse anti-human CD35 antibody (clone E11; AbD Serotec) labelled with 
R-phycoerythrin for 30 min at room temperature in the dark or an isotype control prior to analysis by a 
FACSVerse™ flow cytometer (BD Biosciences). 
 
Results 
Due to unavailability of the clinically developed TT30 we expressed an analog FH-CR2 
fusion protein, which shares 99.6% sequence identity with TT30 (Figure 1A). All proteins 
enrolled in this study were analyzed by SDS-PAGE under reducing and non-reducing conditions 
demonstrating comparable high quality of the preparations (Figure 1B). 
 
Inhibition of AP activation induced by LPS 
Using LPS to induce specifically activation of the AP, we evaluated the potency of FH 
and the C3-opsonin targeted inhibitors to block AP activity. LPS coated to micro-titer plates was 
exposed to serum spiked (separately) with various amounts of either the natural regulator FH or 
one of the engineered inhibitors. Of note, serum already contains FH (~300 to 500 μg/ml 
(Hakobyan et al., 2008; Sofat et al., 2013) equating to ~2-3 μM), so the effective FH 
concentration in this assay, with a final serum proportion of 25%, is about 0.6 μM higher than the 
amount of externally added FH. Addition of purified FH to a final concentration of 2 μM 
completely abolished AP-activation by LPS, which was measured by detecting (or failing to 
detect) the C3-activation products C3b and iC3b (Figure 2A). The estimated IC50 of added FH is 
173 nM (Table I). With an apparent IC50 of 14 nM, FH-CR2 exhibited the highest potency for 
controlling AP-mediated C3b-deposition followed by miniFH-3, miniFH-1 and miniFH-2 
(estimated IC50 of 23 nM, 33 nM and 71 nM, respectively). Thus FH-CR2, miniFH-3, miniFH-1 
and miniFH-2 are about 12-, 8-, 5- and 2-fold more active than FH in inhibiting LPS-induced 
complement activation. The inhibitory potential of FH and miniFH-1 observed here compares 
well to the observations in a previous study in the same LPS-induced AP activation assay 
(Schmidt et al., 2013). With its apparent IC50 of 14 nM, FH-CR2 showed higher absolute 
inhibitory activity in blocking LPS-driven AP-activation than was originally reported for TT30 
(40 nM) (Fridkis-Hareli et al., 2011), when TT30 has been assayed in the Wieslab complement 
system AP ELISA assay. This difference in absolute numbers most likely originates from the 
different serum concentration and detection method used in the Wieslab assay. This observation 
underlines the importance of comparing different complement inhibitors simultaneously in the 
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same assay in order to establish a conclusive ranking of inhibitory potency. 
 
MiniFH is most active in protecting PNH cells from complement AP-mediated lysis 
To probe the complement inhibitory potency of the C3-opsonin targeted inhibitors in a 
more physiological setting, we tested the inhibitor set in a clinically relevant assay of PNH 
erythrocyte lysis in acidified serum (Risitano et al., 2012; Schmidt et al., 2013) with a final serum 
content of 75%. Acidification of serum results in brisk activation (enhanced tick-over activation 
of C3) of the AP simulating a complement activation trigger (Ezzell et al., 1991). Similarly to the 
LPS assay, here the acidified serum was spiked with the C3-opsonin targeted inhibitors prior to 
incubation with patient-derived PNH erythrocytes. Blood SNP genotyping revealed that the PNH 
erythrocytes were of the heterozygous (high/low) genotype for the CR1 expression number 
polymorphism, which represents the most commonly observed CR1 phenotype, and thus areexpected to 
have an intermediate number of CR1 molecules (200-1000) on their surface. A direct 
comparison of CR1 surface expression by flow cytometry between the erythrocytes of a healthy 
donor with a heterozygous high/low CR1 expression phenotype and the PNH patient revealed a 
similar CR1 expression pattern, thereby confirming that the PNH cells supplied for this assay 
exhibit a common CR1 phenotype (Supplemental Figure 2). 
 
In the PNH erythrocyte lysis assay miniFH-1 exhibited the highest inhibitory potency 
with an estimated IC50 of 78 nM, followed by miniFH-3 and miniFH-2 with IC50 values of 112 
nM and 120 nM, respectively (Figure 2B, Table I). FH-CR2 showed an estimated IC50 of 385 nM 
and was substantially less active than any of the miniFH versions. However, FH-CR2 is still 
about twice as active as externally added FH with an estimated IC50 of 887 nM. MiniFH-1 and 
TT30 have already been evaluated in the lysis assay of PNH cells in acidified serum and the 
values obtained here for miniFH-1 and FH-CR2 (from one PNH patient) fit excellently with the 
previously published activities when these two proteins have been tested on PNH erythrocytes 
from two or 20 different PNH patients (respectively) (Risitano et al., 2012; Schmidt et al., 2013). 
The good agreement validates the PNH lysis assay employed here and importantly confirms that 
FH-CR2, which is nearly identical to TT30, shares the same functional activity in protecting PNH 
erythrocytes. In analogy to the inhibition of LPS-induced AP activation, any targeting of the N terminal 
FH regulatory domains to C3-opsonins (as seen in the engineered inhibitors) potentiates 
the regulatory efficiency of FH in protecting patient-derived PNH cells. Of note, the relative 
complement-inhibitory ranking observed for PNH cells differs markedly from the ranking 
observed for LPS-induced complement activation. In protecting PNH cells from AP mediated 
lysis, miniFH-1 is at least 10-fold more active than FH, followed by miniFH versions 2 and 3, 
which exhibit about an 8-fold activity gain over FH, with FH-CR2 being at least twice as active 
as FH. Thus, the miniFH-1 targeting approach is significantly more efficient (~0.2 μM) in the 
protection of host erythrocytes (full inhibition of lysis, Fig 2B) than the FH-CR2 approach (~0.8 
μM). 
 
Equal activity of miniFH and FH-CR2 in protecting rabbit erythrocytes from complement AP mediated 
lysis 
Next we set out to test if the increased efficiency of miniFH analogs over FH-CR2 derives from a 
general higher complement regulatory activity or instead from a higher selectivity for host 
erythrocytes. We therefore tested the AP regulatory activities of miniFH-1 and FH-CR2 on 
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foreign rabbit erythrocytes, which are well known activators of the AP. In this established 
standard assay (here with final serum content of 75%) miniFH-1 and FH-CR2 exhibited similar 
activity, requiring ~1 μM to block lysis (Figure 3, Table I). Since the complement regulatory 
functions for both inhibitors is mediated by the N-terminal portion of FH, and both are targeted to 
C3-degradation products (though different mechanisms) the increased efficiency of miniFH 
proteins on human PNH cells appears to be due to the increased selectivity for host surface 
polyanions, which are recognized by the C-terminal FH domain 20, rather than an intrinsic 
increase in AP regulatory potency. 
 
C3-opsonin targeted inhibitors with AP specificity maintain bactericidal serum activity contrary 
to eculizumab 
Extending this idea of specificity for vulnerable host cell surfaces, we evaluated the effect 
that the AP specific, C3-opsonin targeted inhibitors exert on complement mediated bactericidal 
serum activity. Therefore we compared the impact on serum killing of E. coli cells (final serum 
content of 75%) between untargeted inhibition of the TP by eculizumab with the more selective 
inhibition by miniFH-1 and FH-CR2 (Figure 4). Under a final concentration of 0.3 μM 
eculizumab in this assay, which closely corresponds to the C5 plasma concentration, bacterial 
survival was comparable to heat-inactivated serum. The final eculizumab concentration of 0.3 
μM in this assay may be compared to therapeutic serum levels of the drug typically measured in 
patients of 0.2-1.0 μM (0.035 – 150 μg/ml) (Hillmen et al., 2004). Contrary to eculizumab, both 
targeted inhibitors showed substantially smaller effects on serum bactericidal activity with a 
similar dose-response behavior in this assay. Although not reaching statistical significance, 
differences between the CFU values in the miniFH-1 and FH-CR2 groups were observed, 
particularly when taking the effective concentration for the protection of PNH cells into 
consideration. A final miniFH concentration of 0.2 μM, which was fully protective in the PNH 
assay (Figure 2B), barely interfered with bactericidal serum activity. In contrast, an FH-CR2 
concentration of 0.8 μM, which was required to fully protect PNH erythrocytes, yielded 100-fold 
more surviving bacteria than miniFH-1 at its efficient concentration, which emphasizes the very 
high regulatory selectivity of the miniFH approach for host polyanion-bearing surfaces. 
 
Discussion 
The therapeutic utilization of FH’s regulatory function can be an attractive strategy in 
reestablishing the delicate balance between complement activation and regulation in clinical 
conditions that are primarily AP-mediated (Holers et al., 2013). Although the clinical experience 
with long-term therapeutic inhibition of complement is still limited, selectively inhibiting AP 
activation on self-cells is expected to better preserve the immune surveillance functions of the 
complement cascade. Novel inhibitors that maintain the selectivity of FH but are more potent 
regulators hold great promise for further preclinical and clinical development. 
 
All C3-opsonin targeted inhibitors are more active than FH 
Combining of the N-terminal regulatory domains of FH (CCPs 1-4 or 1-5) with a portion 
that targets the C3b-inactivation products iC3b or C3dg, as seen in all of the C3-opsonin targeted 
inhibitors, clearly potentiates the inhibitory function towards the AP when compared to FH 
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(Figure 2). It is remarkable that this effect can either be achieved by CR2 domains 1-4, which 
bind to the thioester domain (TED) in iC3b and C3dg with a KD of 0.5 μM (van den Elsen and 
Isenman, 2011) or by the C-terminal domains 19-20 in FH, which appear to be cryptic in fulllength 
FH (Oppermann et al., 2006; Schmidt et al., 2013), but when uncoupled from FH bind to 
iC3b and C3dg with an affinity of ~5 μM (Morgan et al., 2011; Schmidt et al., 2013, 2008). 
Recently, the concept of a cryptic C-terminus was also confirmed experimentally (Herbert et al., 2015). 
Hence, different means of targeting complement regulators to sites of ongoing 
complement turnover (presence of iC3b and C3dg opsonins) appears to generally boost 
regulatory capacity, which may be due to the local increase of inhibitor concentration on those 
sites. Remarkably, CR2 domains 1-4 exhibit a 10-fold higher affinity for the C3-inactivation 
products iC3b/C3dg than FH domains 19-20 do (Morgan et al., 2011; Schmidt et al., 2008; van 
den Elsen and Isenman, 2011), but this higher affinity for these late-stage opsonins did not 
translate into higher AP inhibitory activity of FH-CR2 on foreign surfaces like rabbit erythrocyte 
(Figure 3). It can be anticipated that due to faster iC3b/C3dg dissociation rates, which are 
generally associated with a higher KD, miniFH molecules transit faster to surface patches that 
experience a fresh insult of C3b-deposition than FH-CR2 may do, thus compensating for its 
lower affinity to those sites of complement turnover. 
 
Molecular design of engineered inhibitors correlates with specificity for self-surfaces 
The FH-CR2 fusion protein approach (targeting of iC3b/C3dg via CR2; reviewed in 
(Holers et al., 2013)) showed the highest inhibitory activity towards AP activation induced by 
LPS (Figure 2A) and is at least tenfold more active than FH in this assay. In regards to preventing 
lysis of PNH cells the miniFH approach of targeting complement regulation to iC3b/C3dg-sites 
(via an isolated FH C-terminus) was found to be most active (Figure 2B). The activity gain of 
FH-CR2 over FH in the PNH lysis assay is only twofold when compared to the tenfold higher 
activity in the LPS assay. Therefore, on the human PNH erythrocyte surfaces, the FH protection 
mechanism appears to have gained advantageous features in comparison to the activity ranking of 
FH-CR2 and FH in the LPS-based assay. A probable explanation is that FH contains recognition 
sites for host specific polyanionic markers that are absent in FH-CR2. The reason for the higher 
activity of the miniFH proteins over FH-CR2, on host erythrocytes, likely also originates from 
the host-cell recognition properties of FH domains 19-20 (Blaum et al., 2015; Ferreira et al., 
2006; Ferreira and Pangburn, 2007; Meri and Pangburn, 1990; Oppermann et al., 2006; Schmidt 
et al., 2013). Apart from binding to the thioester domain in C3b, iC3b and C3dg, FH domains 19- 
20 also adhere to host specific sialic acid molecules on human tissue, which increases the avidity 
for C3 opsonins present on host surfaces. In comparison to FH the miniFH versions benefit from 
higher availability of the FH domains 19-20, which enables targeting to C3b inactivation 
products; in full-length FH these recognition domains reside in a cryptic conformation. The 
observed activity gain of miniFH-1 over the other miniFH versions most likely results from the 
optimized peptide linker (Schmidt et al., 2013), which allows miniFH-1 to bind simultaneously 
and optimally with all of its domains (FH domains 1-4 and 19-20) to the C3-activation product 
C3b and the host polyanion cell surface markers. The miniFH-2 molecule is a direct fusion of the 
FH domains 1-4 with domains 19-20, whereas miniFH-3 extents these key functional parts of FH 
by FH domain 5 and 18. As a result miniFH versions -2 and -3 are probably unable to bind 
simultaneously to one C3b molecule and thus are predicted to have a different avidity behavior 
for C3b covered surfaces than miniFH-1 has. Nonetheless, all miniFH versions benefit from the 
avidity that was introduced by directly connecting the N-terminal FH domains with domains 19- 
10 
 
20 thus releasing these domains from the natural cryptic C-terminal orientation in FH. Highselectivity for 
host tissue specific polyanions is generally expected to result in a superior safety 
profile since pathogens are commonly void of these surface markers. Indeed, miniFH effectively 
inhibits PNH cell lysis without significantly modulating serum bactericidal properties. Contrary 
to this, complete blockage of the TP by eculizumab abolished bactericidal serum activity, as 
anticipated. Of note though, our bactericidal serum assay solely relies on bacterial killing through 
the terminal MAC, which cannot form under eculizumab, whereas in vivo C3-opsonisation of 
bacteria (still possible under eculizumab) constitutes another anti-bacterial action of complement 
and enhances bacterial clearance by phagocytes. Nonetheless, in the light of the Neisseria 
infections observed under eculizumab, our finding of miniFH’s selective AP complement 
inhibition on PNH erythrocytes is very relevant for future preclinical development. 
 
C3-opsonin targeting and clinical outlook 
Our in vitro comparison shows that, contrary to eculizumab, the C3-opsonin targeted, APspecific 
inhibitors act more selectively on host cells and largely maintain bactericidal serum 
activity. The C3-opsonin targeting approach introduces a bias for protecting host surfaces since 
the objectives of the targeting, i.e. the late stage C3-opsonins iC3b and C3dg (and specific 
polyanions), more readily occur on host surfaces which are (better) equipped with the regulator 
machinery to process C3b to late stage opsonins. Another reason for the marginal interference 
with bactericidal serum activity of miniFH and FH-CR2 may lie in their AP selectivity. Antibodydependent 
and independent CP activation on E. coli has been demonstrated (Wang et al., 2012) 
providing a rationale why AP-specific inhibition interferes to a much lesser extent with the 
bactericidal serum activity. MiniFH-1 and FH-CR2 show similar dose-dependent interference 
with lytic serum activities. However, when the inhibitor concentrations that are needed to fully 
protect the PNH cells from lysis are factored in, a notable difference between the two inhibitors is 
apparent. At the effective concentration in the PNH assay of 0.2 μM, miniFH-1 maintains a 
higher (but not significantly different) bactericidal activity in serum than observed for FH-CR2 at 
0.8 μM. The direct comparison of the different targeting approaches employed in FH-CR2 or 
miniFH shows that the latter approach overall is more selective for PNH erythrocytes. This 
implies that in a potential future clinical application miniFH may mitigate the current safety 
concerns in respect to eculizumab predisposing to Neisseria infections. In addition, targeted 
inhibition may favorably influence dose requirements. While application of FH from external 
sources (Brandstätter et al., 2012; Fakhouri et al., 2010; Schmidt et al., 2011) to patients should 
restore complement regulation, it is evident that a significant quantity of the natural regulator 
would have to be administered to achieve sufficient control over an under-regulated AP. The lysis 
assay of PNH cells in acidified serum herein was performed at a serum concentration of 75%, 
thus resulting in a final FH concentration in the assay of about 1.5- 2.2 μM. Addition of at least 
the same amount of external FH (to achieve a final concentration of externally added FH at 2 
μM) (Figure 2B) was necessary to protect the majority of PNH cells from lysis. Our in vitro 
comparison of C3-opsonin targeted inhibitors, demonstrates that only one tenth (= 0.2 μM) of 
that concentration of externally added FH would have to be achieved if PNH patients were to be 
treated with the most active fusion protein in the PNH assay, miniFH-1. The C3-opsonin 
targetedinhibitors TT30 and miniFH-1 have already demonstrated that those biopharmaceutical 
candidates efficiently prevent C3 opsonization of PNH erythrocytes, which is an effect observed 
under eculizumab therapy and appears to correlate negatively with the hematologic response to 
eculizumab in a substantial subgroup of PNH patients (Risitano et al., 2011, 2009). In the direct 
comparison in this clinically relevant ex vivo models, miniFH-1 is at least 5-fold more active than 
11 
 
FH-CR2 in protecting PNH cells from lysis, which correlates well with the previously estimated 
10-fold increase in activity when two separate studies using the two inhibitors were compared 
(Risitano et al., 2012; Schmidt et al., 2013). This clear and substantial activity gain of the miniFH 
versions (and especially miniFH-1) over TT30 in protecting PNH cells should warrant future 
clinical investigation of this potent class of FH-based and engineered proteins after successful 
completion of ongoing preclinical animal studies. In addition to the subgroup of PNH patients 
that suffer from extravascular hemolysis second to C3-opsonization (Hill et al., 2010; Risitano et 
al., 2009), patients with genetic variants in C5 have been reported that also suffer from a poor 
response to eculizumab (Nishimura et al., 2014). Our findings suggest that the C3-opsonin 
targeted inhibitors may introduce significant clinical benefit to PNH patients, particularly to those 
who currently suffer from suboptimal or poor response to eculizumab. 
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Table 1. Summary of estimated IC50 values for complement AP 
inhibition  
 
  
  
IC50 values for different activator surfacesa 
 
SPIKED 
INHIBITORS 
LPS (ELISA plate) PNH erythrocytes 
 
Rabbit erythrocytes 
FH 
173  
(R2=0.96, CI=130 to 230) 
887  
(R2=0.91, CI=687 to 1146) 
- 
FH-CR2 
14  
(R2=0.92, CI=10 to 22) 
385  
(R2=0.91, CI=314 to 473) 
650 
R2=0.91 
CI=441 to 959 
miniFH-1 
33  
(R2=0.98, CI= 28 to 39) 
 78  
(R2=0.90, CI=62 to 98) 
567 
R2=0.94 
CI=457 to 703 
miniFH-2 
71  
(R2=0.92, CI=52 to 98) 
120  
(R2=0.95, CI=101 to 142) 
- 
miniFH-3 
23  
(R2=0.97, CI=19 to 29) 
112  
(R2=0.83, CI=85 to 142) 
- 
a Values are in nM. 
Estimated IC50 values were obtained by fitting the obtained curves to a 
sigmoidal dose-response using GraphPad Prism software; the goodness 
of the fit is indicated by R2 followed by the 95% confidence interval (CI) 
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